Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Down on somewhat heavy volume
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(192)
•••
Comment by craighenryon Feb 19, 2021 7:46pm
112 Views
Post# 32616745

RE:Down on somewhat heavy volume

RE:Down on somewhat heavy volume
zwerp2000 wrote: Not exactly what you want to see after a conference. Maybe investors were hoping for news.. this company continues to under deliver. Disappointing. Maybe one day it will change but it's been years and years the company is still spinning its wheels, pushing out timelines etc 


Sell your shares and move on you whining little child!! You are a loser and bitter towards JD because YOU are losing money on YOUR Bioasis investment. You are always the victim!! JD didn't hold a gun to your head and make you buy bioasis shares. Own it pu ssy! Take accountability for your trades!! JD and others are entitled to post their DD and their thoughts on bioasis. If they are right or wrong whatever happens in this saga happens. Big deal if JD is wrong. Hell I have been wrong on bioasis for 9 years......but I am not on here crying like a little child blaming JD because he said "18 and 4 and many more" You are the ONLY one to blame. That being said the coward you are will always find someone to blame!!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities